All

Results: 17317-17328 of 78284

4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US).

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

PR Newswire associated0

CHAGEE Releases "2025 Year-End Tea Friends Review": Global Stores Span 8 Countries Across 2 Continents, Annual Tea Procurement Exceeds 10,000 Tons

CHiQ Named One of the '2025-2026 Global Smart Home Brands Top 10' at CES

Invitation to presentation of EQT AB's Year-end Report 2025

PR Newswire associated0

Astronergy Launches ASTRO N7 Pro to Unleash Pro Performance

Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference

Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI

"STRIKE WORLD: Deadverse Reloaded the Anime" Available on Prime Video Worldwide from January 7, 2026

PR Newswire associated0

Hyundai Mobis Forms Strategic Collaboration Framework with Boston Dynamics!

PROMISE Technology to showcase AI-Ready Storage Infrastructure for Smart City and IVA Surveillance at Intersec Dubai 2026

PR Newswire associated0

Hisense Debuts 116UXS and XR10, Advancing RGB MiniLED into a New Era at CES 2026